Chronic HBV Infection Clinical Trial
Official title:
Serum HBV RNA Level Monitoring During Chronic Hepatitis B Virus Infection Especialy in Patients Undergoing Long-term Nucleos(t)Ide Analoguage Treatment
NCT number | NCT03909191 |
Other study ID # | HBV RNA2016 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 1, 2016 |
Est. completion date | May 1, 2020 |
Verified date | January 2021 |
Source | Changhai Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
As an alternative biomarker of intrahepatic covalently closed circular DNA(cccDNA) transcriptional activity, hepatitis B virus(HBV)RNA may evolve during long-lasting virus-host interactionsduring chronic hepatitis B viral infection.The distribution pattern of serum HBV RNA levels in the natural course of chronic HBV infection remains unclear. Furthermore,serum HBV RNA was associated with response to NAs. So it may be another clinical surrogate marker for intrahepatic cccDNA level after long-term NAs treatment and be used to monitor NAs therapy. The aim of this study was to evaluate thelevels of HBV RNA during the natural courseof CHB and the role in distinguishingthe natural phases of HBV infection and to investigate whether serum HBV RNA level at the end of long-term NAs treatment had a similar or better predict effect on off-therapy relapse than serum HBsAg titer.
Status | Completed |
Enrollment | 454 |
Est. completion date | May 1, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - 18 to 70 years old, - no gender restriction, - serum HBsAg positive than 6 months, - can understand and sign informed consent, - good compliance. Exclusion Criteria: - coinfected with other hepatotropic virus such as hepatitis C virus,hepatitis D -virus,hepatitis E and hepatitis A etc; - coinfected with HIV, - markers such as ceruloplasmin, anti-nuclear antibodies and anti-mitochondrial antibodies for co-existent autoimmune and metabolic liver diseases were positive, - with hepatocellular carcinoma(HCC) - with uncontrollable extrehepatic disease, - received glucocorticoid or other immune inhibitor therapy, - pregnancy. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Changhai Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | serum HBV RNA value in treatment naive patients with chronic HBV infection were tested by using HBV SAT | serum HBV RNA level in patients with chronic HBV infection during different natural history stage were were compared. The relationship between serum HBV RNA and other viral markers,such as HBV DNA,HBeAg and HBsAg, were determined. | serum HBV RNA level were measured 24hs after the enrollment | |
Primary | End of treatment serum HBV RNA levels predict the 24-month off-therapy viral rebound | End of treatment serum HBV RNA in patients after long-term nucleos(t)ide analog therapy were tested and the predictive effect of EOT HBV RNA value on 24-month off-therapy viral rebound were determined. | Change in serum HBV DNA levels from stopping baseline to 24 month after drug cessation was determined | |
Secondary | serum HBV RNA in patients receiving long-term NAs therapy were tested at different time point | serum HBV RNA change pattern along long-term NAs therapy wad determined and the relationship between HBV RNA and HBV DNA or HBsAg during NAs therapy were also determined | 48 hrs after enrollment the serun HBV RNA level were tested | |
Secondary | Number of patients with evaluate HBV DNA relapse(> 20,000 IU/mL) through 96 weeks off-therapy | the cumulative viral relapse rates at the 1st and 2nd year off-therapy were calculated | viral rebound rates were calculated from stopping baseline to 24 month after drug cessation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04470388 -
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
|
Phase 1 | |
Completed |
NCT05019040 -
Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01943799 -
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
|
Phase 2 | |
Recruiting |
NCT05792761 -
A Study on Antiviral Treatment of Chronic Hepatitis B in Children
|
N/A | |
Completed |
NCT05468060 -
Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04008004 -
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
|
Phase 1 | |
Active, not recruiting |
NCT05734807 -
A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
|
Phase 2 | |
Completed |
NCT06029634 -
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
|
||
Completed |
NCT04147208 -
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
|
Phase 2 | |
Completed |
NCT03664518 -
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
|
Phase 2 | |
Completed |
NCT05542979 -
A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection
|
Phase 1 | |
Active, not recruiting |
NCT03903796 -
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
|
Phase 3 | |
Completed |
NCT05851261 -
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects
|
Phase 1 |